Therapeutic drug monitoring-guided linezolid salvage therapy for Lacticaseibacillus paracasei infective endocarditis: A case report
Abstract
We report a rare case of infective endocarditis (IE) caused by Lacticaseibacillus paracasei (formerly Lactobacillus paracasei) that was managed with intravenous linezolid as salvage therapy. A 38-year-old woman presented with a three-week history of intermittent fever and cutaneous manifestations, and was diagnosed with IE caused by Lacticaseibacillus paracasei. The initial ampicillin/clindamycin therapy was discontinued due to suspected drug fever, and subsequent levofloxacin monotherapy was complicated by a drug-induced rash. Linezolid monotherapy was therefore initiated as salvage therapy, with dosing carefully adjusted via therapeutic drug monitoring (TDM) to maintain trough levels between 2 and 8 μg/mL. This approach enabled prolonged treatment without significant adverse effects, including thrombocytopenia. To our knowledge, reports of Lactobacillus IE managed with linezolid TDM are ecseedingly rare. This case suggests that linezolid, guided by TDM, may be considered as a salvage option for Lactobacillus IE.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.